{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:28:44Z","timestamp":1788560924107,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guiding Project of Science and Technology Bureau of Enshi Tujia and Miao Autonomous Prefecture","award":["JCY2019000031"],"award-info":[{"award-number":["JCY2019000031"]}]},{"name":"Science and Technology Department of Sichuan Province,","award":["Project of Science and Technology Department of Sichuan Province\/2021YJ0184"],"award-info":[{"award-number":["Project of Science and Technology Department of Sichuan Province\/2021YJ0184"]}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"crossref","award":["National Key R&D Plan\/2017YFC1308504"],"award-info":[{"award-number":["National Key R&D Plan\/2017YFC1308504"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Botulinum toxin (BoNT) injection is an important adjunctive method to treat sialorrhea. The purpose of this systematic review was to analyze the effect and safety of BoNT injections in the intervention of sialorrhea with Parkinson\u2019s disease (PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We searched PubMed, Web Of Science (WOS), Scopus, Cochrane CENTRAL, and Embase from inception until April 2022. Randomized controlled trials or randomized crossover trials comparing BoNT with placebo in sialorrhea with PD were eligible. PRISMA guidelines were used to carry out the meta-analysis. The Drooling Severity Frequency Scale (DSFS) score and the number of adverse events (AEs) were the primary and secondary outcomes, respectively. Standardized mean differences (SMDs) and risk differences (RDs) are used to express continuous and categorical outcomes, respectively. Heterogeneity among these studies was evaluated using I\n                      <jats:sup>2<\/jats:sup>\n                      tests. We used the GRADE tool to assess the certainty of evidence (COE).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight articles involving 259 patients compared BoNT injections with a placebo for PD with sialorrhea. This meta-analysis showed a significant reduction in DSFS scores\u00a0between BoNT injections and placebo (SMD=-0.98; 95% CI, -1.27 to 0.70,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001; COE: high). This meta-analysis showed a significant difference in AEs between BoNT injections and placebo (RD=0.15; 95% CI, 0.05 to 0.24,\n                      <jats:italic>p<\/jats:italic>\n                      =0.002; COE: low).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The pooled results suggest that BoNT injections have some effect on DSFS scores with sialorrhea caused by PD. There are also mild adverse events, which generally recover within a week or so. The results indicate that BoNT injection is one of the treatments for sialorrhea caused by PD, but we need to pay attention to adverse events. In addition, the follow-up time was extended to observe oral hygiene, ulceration or dental caries, and digestive function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Our review protocol was registered on PROSPERO (42021288334).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-023-00694-7","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:01:57Z","timestamp":1697108517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-7131","authenticated-orcid":false,"given":"Chun-Lan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5574-677X","authenticated-orcid":false,"given":"Jia-Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-chao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-4164","authenticated-orcid":false,"given":"Yun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"issue":"4","key":"694_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/11208120-000000000-00000","volume":"14","author":"KP Garnock-Jones","year":"2012","unstructured":"Garnock-Jones KP. Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions. Paediatr Drugs. 2012;14(4):263\u20139. https:\/\/doi.org\/10.2165\/11208120-000000000-00000.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"694_CR2","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/toxins5051010","volume":"5","author":"AA Lakraj","year":"2013","unstructured":"Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins. Toxins. 2013;5(5):1010\u201331. https:\/\/doi.org\/10.3390\/toxins5051010.","journal-title":"Toxins"},{"issue":"2","key":"694_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0003489418808305","volume":"128","author":"OF Calim","year":"2019","unstructured":"Calim OF, Hassouna HNH, Yildirim YS, Dogan R, Ozturan O. Pediatric Sialorrhea: Submandibular Duct Rerouting and Intraparotid Botulinum Toxin A Injection With Literature Review. Ann Otol Rhinol Laryngol. 2019;128(2):104\u201312. https:\/\/doi.org\/10.1177\/0003489418808305.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"2","key":"694_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/practneurol-2016-001515","volume":"17","author":"AJ McGeachan","year":"2017","unstructured":"McGeachan AJ, McDermott CJ. Management of oral secretions in neurological disease. Pract Neurol. 2017;17(2):96\u2013103. https:\/\/doi.org\/10.1136\/practneurol-2016-001515.","journal-title":"Pract Neurol"},{"key":"694_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.toxicon.2017.08.011","volume":"147","author":"M Hallett","year":"2018","unstructured":"Hallett M. Mechanism of action of botulinum neurotoxin: Unexpected consequences. Toxicon. 2018;147:73\u20136. https:\/\/doi.org\/10.1016\/j.toxicon.2017.08.011.","journal-title":"Toxicon"},{"issue":"16","key":"694_CR6","first-page":"1678","volume":"128","author":"H Rossow","year":"2012","unstructured":"Rossow H, Kinnunen PM, Nikkari S. Botulinum toxin as a biological weapon. Duodecim. 2012;128(16):1678\u201384 PMID: 23025151.","journal-title":"Duodecim."},{"issue":"8","key":"694_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.27072","volume":"32","author":"J Jankovic","year":"2017","unstructured":"Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017;32(8):1131\u20138. https:\/\/doi.org\/10.1002\/mds.27072.","journal-title":"Mov Disord"},{"issue":"4","key":"694_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","volume":"77","author":"SH Isaacson","year":"2020","unstructured":"Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, et al. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. JAMA Neurol. 2020;77(4):461\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4565.","journal-title":"JAMA Neurol"},{"key":"694_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jocn.2018.02.011","volume":"51","author":"K Sridharan","year":"2018","unstructured":"Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials. J Clin Neurosci. 2018;51:12\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2018.02.011.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"694_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40120-019-00155-6","volume":"8","author":"WH Jost","year":"2019","unstructured":"Jost WH, Baeumer T, Laskawi R, Slawek J, Spittau B, Steffen A, et al. Therapy of Sialorrhea with Botulinum Neurotoxin. Neurol Therapy. 2019;8(2):273\u201388. https:\/\/doi.org\/10.1007\/s40120-019-00155-6.","journal-title":"Neurol Therapy"},{"issue":"1","key":"694_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ene.15083","volume":"29","author":"YC Yu","year":"2022","unstructured":"Yu YC, Chung CC, Tu YK, Hong CT, Chen KH, Tam KW, et al. Efficacy and safety of botulinum toxin for treating sialorrhea: A systematic review and meta-analysis. Eur J Neurol. 2022;29(1):69\u201380. https:\/\/doi.org\/10.1111\/ene.15083.","journal-title":"Eur J Neurol"},{"issue":"s1","key":"694_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/jpg-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-s8. https:\/\/doi.org\/10.3233\/jpg-181474.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"694_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 2021;20(5):385\u201397. https:\/\/doi.org\/10.1016\/s1474-4422(21)00030-2.","journal-title":"Lancet Neurol"},{"issue":"9423","key":"694_CR14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/s0140-6736(04)16305-8","volume":"363","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt JG, Ransom BR. Parkinson\u2019s disease. Lancet. 2004;363(9423):1783\u201393. https:\/\/doi.org\/10.1016\/s0140-6736(04)16305-8.","journal-title":"Lancet"},{"issue":"8","key":"694_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna). 2017;124(8):901\u20135. https:\/\/doi.org\/10.1007\/s00702-017-1686-y.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"694_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12883-020-01996-7","volume":"20","author":"G AlMahadin","year":"2020","unstructured":"AlMahadin G, Lotfi A, Zysk E, Siena FL, Carthy MM, Breedon P. Parkinson\u2019s disease: current assessment methods and wearable devices for evaluation of movement disorder motor symptoms - a patient and healthcare professional perspective. BMC Neurol. 2020;20(1):419. https:\/\/doi.org\/10.1186\/s12883-020-01996-7.","journal-title":"BMC Neurol"},{"issue":"1","key":"694_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75(1):9\u201310. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3299.","journal-title":"JAMA Neurol"},{"issue":"3","key":"694_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.parkreldis.2014.12.031","volume":"21","author":"KR Chaudhuri","year":"2015","unstructured":"Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AH, Brown RG, et al. The burden of non-motor symptoms in Parkinson\u2019s disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord. 2015;21(3):287\u201391. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.031.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"694_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol. 2022;21(1):89\u2013102. https:\/\/doi.org\/10.1016\/s1474-4422(21)00330-6.","journal-title":"Lancet Neurol"},{"issue":"7","key":"694_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350. https:\/\/doi.org\/10.1038\/nrn.2017.62.","journal-title":"Nat Rev Neurosci"},{"key":"694_CR21","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2147\/NDT.S213917","volume":"15","author":"N Hermanowicz","year":"2019","unstructured":"Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson\u2019s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019;15:2205\u201312. https:\/\/doi.org\/10.2147\/NDT.S213917.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"694_CR22","doi-asserted-by":"publisher","unstructured":"Mukhtar S, Imran R, Zaheer M, Tariq H. Frequency of non-motor symptoms in Parkinson's disease presenting to tertiary care centre in Pakistan: an observational, cross-sectional study. Bmj Open. 2018;8(5).\u00a0https:\/\/doi.org\/10.1136\/bmjopen-2017-019172.","DOI":"10.1136\/bmjopen-2017-019172"},{"issue":"3","key":"694_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0b013e31827deb74","volume":"80","author":"TK Khoo","year":"2013","unstructured":"Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O\u2019Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276\u201381. https:\/\/doi.org\/10.1212\/WNL.0b013e31827deb74.","journal-title":"Neurology"},{"issue":"3","key":"694_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson\u2019s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308\u201312. https:\/\/doi.org\/10.1136\/jnnp.69.3.308.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"694_CR25","doi-asserted-by":"publisher","first-page":"175628641988860","DOI":"10.1177\/1756286419888601","volume":"12","author":"F Morgante","year":"2019","unstructured":"Morgante F, Bavikatte G, Anwar F, Mohamed B. The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin\u00ae). Ther Adv Neurol Disord. 2019;12:1756286419888601. https:\/\/doi.org\/10.1177\/1756286419888601.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"694_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00415-009-5098-2","volume":"256","author":"JG Kalf","year":"2009","unstructured":"Kalf JG, de Swart BJ, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in Parkinson\u2019s disease: a systematic review. J Neurol. 2009;256(9):1391\u20136. https:\/\/doi.org\/10.1007\/s00415-009-5098-2.","journal-title":"J Neurol"},{"key":"694_CR27","doi-asserted-by":"publisher","unstructured":"Isaacson J, Patel S, Torres-Yaghi Y, Pagan F. Sialorrhea in Parkinson's Disease. Toxins. 2020;12(11).\u00a0https:\/\/doi.org\/10.3390\/toxins12110691.","DOI":"10.3390\/toxins12110691"},{"key":"694_CR28","doi-asserted-by":"publisher","unstructured":"Jost WH. Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal. Toxins (Basel). 2021;13(2).\u00a0https:\/\/doi.org\/10.3390\/toxins13020087.","DOI":"10.3390\/toxins13020087"},{"issue":"4","key":"694_CR29","first-page":"213","volume":"22","author":"H Bagheri","year":"1999","unstructured":"Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O\u2019Connell D, Senard JM, et al. A study of salivary secretion in Parkinson\u2019s disease. Clin Neuropharmacol. 1999;22(4):213\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"694_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/jprls.S177409","volume":"9","author":"N Miller","year":"2019","unstructured":"Miller N, Walshe M, Walker RW. Sialorrhea in Parkinson\u2019s disease: prevalence, impact and management strategies. Res Rev Parkinson. 2019;9:17\u201328. https:\/\/doi.org\/10.2147\/jprls.S177409.","journal-title":"Res Rev Parkinson"},{"key":"694_CR31","doi-asserted-by":"publisher","unstructured":"Polychronis S, Nasios G, Dardiotis E, Messinis L, Pagano G. Pathophysiology and Symptomatology of Drooling in Parkinson's Disease. Healthcare (Basel). 2022;10(3).\u00a0https:\/\/doi.org\/10.3390\/healthcare10030516.","DOI":"10.3390\/healthcare10030516"},{"issue":"6","key":"694_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00455-018-9906-7","volume":"33","author":"H Reynolds","year":"2018","unstructured":"Reynolds H, Miller N, Walker R. Drooling in Parkinson\u2019s Disease: Evidence of a Role for Divided Attention. Dysphagia. 2018;33(6):809\u201317. https:\/\/doi.org\/10.1007\/s00455-018-9906-7.","journal-title":"Dysphagia"},{"issue":"3","key":"694_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.nbd.2011.10.014","volume":"46","author":"MG Cersosimo","year":"2012","unstructured":"Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2012;46(3):559\u201364. https:\/\/doi.org\/10.1016\/j.nbd.2011.10.014.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"694_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795\u2013808. https:\/\/doi.org\/10.1136\/jnnp-2019-322338.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"694_CR35","doi-asserted-by":"publisher","unstructured":"Ruiz-Roca JA, Pons-Fuster E, Lopez-Jornet P. Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review. J Clin Med. 2019;8(3).\u00a0https:\/\/doi.org\/10.3390\/jcm8030317.","DOI":"10.3390\/jcm8030317"},{"key":"694_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-023-04981-9","author":"LC Santos Junior","year":"2023","unstructured":"Santos Junior LC, Santos JR, Reis A, Faria ESAL, Leal PC. Effectiveness of the pharmacological treatments for sialorrhea in patients with Parkinson\u2019s disease: a systematic review and network meta-analysis. Clin Oral Investig. 2023. https:\/\/doi.org\/10.1007\/s00784-023-04981-9.","journal-title":"Clin Oral Investig"},{"key":"694_CR37","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1002\/mds.26295","volume":"30","author":"P Narayanaswami","year":"2015","unstructured":"Narayanaswami P, Tarulli A, Raynor E, Gautam S, Geisbush T, Tarsy D. Randomized double-blind placebo-controlled cross-over study of incobotulinum toxin A for troublesome drooling in Parkinson\u2019s disease (PD). Mov Disord. 2015;30:S203. https:\/\/doi.org\/10.1002\/mds.26295.","journal-title":"Mov Disord"},{"key":"694_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178\u201389. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.03.001.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"694_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5606\/ArchRheumatol.2020.7375","volume":"35","author":"M Khodashahi","year":"2020","unstructured":"Khodashahi M. Comparison of the therapeutic effects of rivaroxaban versus warfarin in antiphospholipid syndrome: a systematic review. Arch Rheumatol. 2020;35(1):107\u201316. https:\/\/doi.org\/10.5606\/ArchRheumatol.2020.7375.","journal-title":"Arch Rheumatol"},{"issue":"6","key":"694_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/mds.10420","volume":"18","author":"F Mancini","year":"2003","unstructured":"Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling Parkinsonism. Mov Disord. 2003;18(6):685\u20138. https:\/\/doi.org\/10.1002\/mds.10420.","journal-title":"Mov Disord"},{"issue":"5","key":"694_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","volume":"64","author":"JL Brozek","year":"2009","unstructured":"Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669\u201377. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.01973.x.","journal-title":"Allergy."},{"issue":"1","key":"694_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease. Neurology. 2004;62(1):37\u201340. https:\/\/doi.org\/10.1212\/01.WNL.0000101713.81253.4C.","journal-title":"Neurology"},{"issue":"5","key":"694_CR43","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/mds.20793","volume":"21","author":"G Lagalla","year":"2006","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson\u2019s disease: A double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21(5):704\u20137. https:\/\/doi.org\/10.1002\/mds.20793.","journal-title":"Mov Disord"},{"issue":"4","key":"694_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","volume":"256","author":"G Lagalla","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling. J Neurol. 2009;256(4):563\u20137. https:\/\/doi.org\/10.1007\/s00415-009-0085-1.","journal-title":"J Neurol"},{"issue":"2","key":"694_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.23929","volume":"27","author":"R Chinnapongse","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: A prospective double-blind trial. Mov Disord. 2012;27(2):219\u201326. https:\/\/doi.org\/10.1002\/mds.23929.","journal-title":"Mov Disord"},{"key":"694_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.07.001","volume":"30","author":"P Narayanaswami","year":"2016","unstructured":"Narayanaswami P, Geisbush T, Tarulli A, Raynor E, Gautam S, Tarsy D, et al. Drooling in Parkinson\u2019s disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins. Parkinsonism Relat Disord. 2016;30:73\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.07.001.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"694_CR47","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10072-018-3279-4","volume":"39","author":"J Tiigim\u00e4e-Saar","year":"2018","unstructured":"Tiigim\u00e4e-Saar J, Tamme T, Rosenthal M, Kadastik-Eerme L, Taba P. Saliva changes in Parkinson\u2019s disease patients after injection of Botulinum neurotoxin type A. Neurol Sci. 2018;39(5):871\u20137. https:\/\/doi.org\/10.1007\/s10072-018-3279-4.","journal-title":"Neurol Sci"},{"key":"694_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5004","volume":"345","author":"CL Tomlinson","year":"2012","unstructured":"Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, et al. Physiotherapy intervention in Parkinson\u2019s disease: systematic review and meta-analysis. BMJ. 2012;345: e5004. https:\/\/doi.org\/10.1136\/bmj.e5004.","journal-title":"BMJ"},{"key":"694_CR49","doi-asserted-by":"publisher","unstructured":"Ruiz-Roca JA, Pons-Fuster E, Lopez-Jornet P. Effectiveness of the botulinum toxin for treating sialorrhea in patients with parkinson\u2019s disease: A systematic review. Journal of Clinical Medicine. 2019;8(3).\u00a0https:\/\/doi.org\/10.3390\/jcm8030317.","DOI":"10.3390\/jcm8030317"},{"issue":"1","key":"694_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00702-015-1416-2","volume":"123","author":"WH Jost","year":"2016","unstructured":"Jost WH. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson\u2019s disease. J Neural Transm. 2016;123(1):51\u20135. https:\/\/doi.org\/10.1007\/s00702-015-1416-2.","journal-title":"J Neural Transm"},{"issue":"9","key":"694_CR51","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.3390\/toxins7093758","volume":"7","author":"M Mazlan","year":"2015","unstructured":"Mazlan M, Rajasegaran S, Engkasan JP, Nawawi O, Goh KJ, Freddy SJ. A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-a for sialorrhea treatment in asian adults with neurological diseases. Toxins (Basel). 2015;7(9):3758\u201370. https:\/\/doi.org\/10.3390\/toxins7093758.","journal-title":"Toxins (Basel)"},{"issue":"5","key":"694_CR52","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.20784","volume":"21","author":"OR Tumilasci","year":"2006","unstructured":"Tumilasci OR, Cers\u00f3simo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson\u2019s disease. Mov Disord. 2006;21(5):660\u20137. https:\/\/doi.org\/10.1002\/mds.20784.","journal-title":"Mov Disord"},{"issue":"10","key":"694_CR53","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.1002\/lary.25222","volume":"125","author":"I Cardona","year":"2015","unstructured":"Cardona I, Saint-Martin C, Daniel SJ. Effect of recurrent onabotulinum toxin A injection into the salivary glands: An ultrasound measurement. Laryngoscope. 2015;125(10):E328\u201332. https:\/\/doi.org\/10.1002\/lary.25222.","journal-title":"Laryngoscope"},{"issue":"8","key":"694_CR54","doi-asserted-by":"publisher","DOI":"10.2106\/jbjs.Rvw.18.00153","volume":"7","author":"I Multani","year":"2019","unstructured":"Multani I, Manji J, Tang MJ, Herzog W, Howard JJ, Graham HK. Sarcopenia, cerebral palsy, and botulinum toxin type A. JBJS Rev. 2019;7(8): e4. https:\/\/doi.org\/10.2106\/jbjs.Rvw.18.00153.","journal-title":"JBJS Rev"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00694-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T06:31:58Z","timestamp":1700289118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00694-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00694-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2009899\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agreed to be published","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}